Diabetic Retinopathy Market size to exceed $11bn by 2023

1
Diabetic Retinopathy Market size to exceed 11bn
by 2023 Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
2
Key Insights from Diabetic Retinopathy Market

• The global diabetic retinopathy market revenue
  was pegged at USD 6.5 billion in 2015, and
  anticipated to reach CAGR of 6.9 by 2023 raising
  the market value to USD 11.1 billion.
• North America led the global diabetic retinopathy
  market share, with more than 38 of 2015 revenue.
  Favorable government initiatives to curb rising
  burden of diabetes disorders, innovation trends,
  and quick access to treatment options drive
  regional penetration.
• Non-proliferative segment dominated the global
  diabetic retinopathy market share in 2015, at
  more than USD 4.5 billion in revenue  

3
Continued...

• Europe diabetic retinopathy market share, with
  Germany and UK bringing in over 47 revenue in
  2015, looks poised at grow at 6.8 CAGR. Brazil
  diabetic retinopathy market dominated Latin
  America, at 36 revenue contribution in 2015.
• Strategic initiatives such as collaborations, and
  marketing agreements to share research costs may
  see new entrants enter the industry. Presence of
  a large geriatric population base across China,
  India and Japan, along with rising disposable
  incomes, and greater demand for early retinal
  screening in APAC should further enhance growth.
• Bayer, Regeneron, Novartis, Kowa, BCN, Actavis
  and Ampio are key participants in this industry.

4
U.S. Diabetic Retinopathy Market size, by
management, 2012 - 2023 (USD Million)

5

Browse Full Market Research Report On Diabetic
Retinopathy Market _at_ http//goo.gl/uIZjDb
Request for a Sample of this Research Report
_at_ https//www.gminsights.com/request-sample/detail
/486 https//www.gminsights.com/request-sample/det
ail/49
6
360 Analysis

• Product Analysis
• Non-proliferative retinopathy dominated the
  overall market size estimated to exceed to more
  than USD 4.5 billion in 2015. Increased
  occurrence of diabetes, lack of diagnosis at
  right time, and non-compliant retinal screening
  of diabetic patients are projected to propel the
  growth of non-proliferative diabetic retinopathy
  market share.
• Regional Analysis
• North America was the largest regional avenue
  driven by U.S., with revenue target of more than
  USD 4 billion by 2023. Increasing regional access
  to anti-VEGF products including Eylea, Avastin,
  and Lucentis, and rising awareness for early
  detection in order to prevent further blindness
  associated with diabetes will drive demand.
• Competitive Market Share
• Global diabetic retinopathy market was dominated
  by Regeneron Pharmaceuticals, Inc. and Bayer
  Pharmaceuticals collectively grabbing more than
  40 share in the overall market in 2015 majorly
  owing to high market penetration rates of Eylea
  in regions outside the U.S.

7
Stay In Touch Website www.gminsights.com Soci
al Media